Enerzair Breezhaler is an asthma medicine for inhalation. It is used for maintenance (regular) treatment in adults whose asthma is not controlled well enough with inhaled long-acting beta-2 agonist together with a high dose of an inhaled corticosteroid. It should be used for patients who have had at least one asthma attack (exacerbation) in the last year. Enerzair Breezhaler contains the active substances indacaterol, glycopyrronium bromide and mometasone.
Therapeutic Indication
### Therapeutic indication Enerzair Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
Therapeutic Area (MeSH)
N/AATC Code
R03AL
ATC Item
抗胆碱能与抗胆碱能结合/三重组合与糖皮质激素
Pharmacotherapeutic Group
Drugs for obstructive airway diseases
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Enerzair Breezhaler
Medicine Name
Enerzair Breezhaler
Aliases
N/ANo risk management plan link.
